At the forefront of CAR-T, regenerative medicine, genomics and pharmaceutical research and development
Health
Boyalife Health is comprised of the company’s diverse healthcare business, including automated cellular processing, stem cell banking, regenerative medicine, immune-oncology and anti-aging.
Genomics
Located in Tianjin, Boyalife Genomics is a leading developer of animal embryo and animal cloning technologies that are used to help protect critically endangered species, to improve beef cattle yields for the Chinese market, and also to clone companion and highly-specialized service dogs.
Pharma
Boyalife Pharmaceuticals is engaged in the research and development of innovative therapies addressing a broad range of disease areas, including central nervous system, cardiovascular, and cancer.
Car-TXpress
Boyalife’s cell processing affiliate, Cesca Therapeutics, is working to enter the rapidly-emerging CAR-T and immune-oncology space though development of CAR-TXpress™. CAR-TXpress, which is based on its proprietary AutoXpress platform technology, can facilitate the automated manufacture of high-quality, clinical-grade CAR-T cells at scale.
News
Founded in 2009 as the International Consortium of Stem Cell Research (INCOSC), Boyalife Group is a privately-held global biopharmaceutical holding company with 30 subsidiaries and affiliated companies operating in three distinct business segments: 1) cellular processing and biobanking for regenerative medicine, CAR-T and other emerging immunotherapies, 2) genomics and 3) drug discovery. Boyalife Group is headquarted in Wuxi City, China, and maintains operations in Tianjin, Shenzhen, Beijing, Seoul, South Korea, New Delhi, India and Sacramento, California, USA. READ MORE
Founded in 2009 as the International Consortium of Stem Cell Research (INCOSC), Boyalife Group is a privately-held global biopharmaceutical holding company with 30 subsidiaries and affiliated companies operating in three distinct business segments: 1) cellular processing and biobanking for regenerative medicine, CAR-T and other emerging immunotherapies, 2) genomics and 3) drug discovery. Boyalife Group is headquarted in Wuxi City, China, and maintains operations in Tianjin, Shenzhen, Beijing, Seoul, South Korea, New Delhi, India and Sacramento, California, USA. READ MORE